Boundless Bio, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Zachary Hornby
- Full Time Employees
- 28
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9880 Campus Point Drive San Diego CA United States of America 92121
- IPO Date
- Mar 28, 2024
- CIK
- 0001782303
- Website
- boundlessbio.com
- Similar Companies
- Business
- Boundless Bio, Inc. (NASDAQ: BOLD) is a clinical-stage precision oncology company that develops extrachromosomal DNA (ecDNA)-directed therapeutics (ecDTx) targeting oncogene-amplified cancers, which affect more than 14% of cancer patients worldwide; its lead product candidate, BBI-355, is an oral, selective checkpoint kinase 1 (CHK1) inhibitor in Phase 1/2 POTENTIATE clinical trials evaluating safety and antitumor activity as monotherapy and in combinations for solid tumors with oncogene amplifications; BBI-825, an oral ribonucleotide reductase (RNR) inhibitor, was evaluated in the Phase 1/2 STARMAP trial for solid tumors including BRAF V600E- or KRAS G12C-mutated colorectal cancers with resistance amplifications but not advanced beyond Part 1 due to pharmacokinetic challenges and competitive landscape considerations; BBI-940, a selective kinesin degrader targeting ecDNA segregation, was declared a development candidate with an investigational new drug application planned for the first half of 2026; the company also offers the proprietary Spyglass platform for identifying synthetic lethal targets in ecDNA-positive cancers and ECHO, a diagnostic algorithm detecting ecDNA via next-generation sequencing for patient selection in clinical trials. Founded in 2018 and headquartered in San Diego, California, the company operates primarily in the United States with a focus on replication stress, DNA assembly/repair, and segregation vulnerabilities in aggressive solid tumors. Recent strategic changes include portfolio prioritization in May 2025 to focus on a novel BBI-355/BBI-825 combination therapy with clinical initiation planned for late 2025, discontinuation of certain BBI-355 monotherapy and combination arms due to narrow therapeutic index and tolerability issues, declaration of BBI-940 alongside workforce reduction extending cash runway into the first half of 2028, and December 2024 leadership transitions with Chief Medical Officer Klaus Wagner and Chief Business Officer Neil Abdollahian departing and James L. Freddo appointed interim Chief Medical Officer.
Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)
BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy
Boundless Bio: An Underestimated Biotech With A First-In-Class EcDNA Targeted Kinesin Degrader
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
NurExone Announces Corporate Updates
DOT'S® INTRODUCES DOT'S ORIGINAL SNACK MIX - A BOLD NEW TAKE ON SNACKING
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Boundless Bio to Participate in the Leerink Global Healthcare Conference
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
BUBBA® UNVEILS A BOLD, NEW BRAND IDENTITY AND NEXT-GEN WATER BOTTLE DESIGNS, TURNING EVERYDAY HYDRATION INTO PERSONAL EXPRESSION
21shares launches BOLD ETP combining bitcoin and gold in a single regulated product